Triple
T5793351
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | COMP |
E128447
|
entity |
| Predicate | usesLegalBasis |
P125
|
FINISHED |
| Object |
Regulation (EC) No 141/2000 on orphan medicinal products
Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
|
E546469
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Regulation (EC) No 141/2000 on orphan medicinal products | Statement: [COMP, usesLegalBasis, Regulation (EC) No 141/2000 on orphan medicinal products]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Regulation (EC) No 141/2000 on orphan medicinal products Context triple: [COMP, usesLegalBasis, Regulation (EC) No 141/2000 on orphan medicinal products]
-
A.
Regulation (EC) No 726/2004
Regulation (EC) No 726/2004 is an EU law that establishes the centralized procedure for the authorization and supervision of medicinal products and defines the role and powers of the European Medicines Agency.
-
B.
Orphan Drug Act of 1983
The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
-
C.
Committee for Orphan Medicinal Products
The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
-
D.
Regulation (EC) No 45/2001
Regulation (EC) No 45/2001 is an EU law that sets out data protection rules for the processing of personal data by EU institutions and bodies.
-
E.
Council Regulation (EC) No 1/2003
Council Regulation (EC) No 1/2003 is a key European Union law that modernized and decentralized the enforcement of EU competition rules, particularly Articles 101 and 102 of the Treaty on the Functioning of the European Union.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Regulation (EC) No 141/2000 on orphan medicinal products Triple: [COMP, usesLegalBasis, Regulation (EC) No 141/2000 on orphan medicinal products]
Generated description
Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Regulation (EC) No 141/2000 on orphan medicinal products Target entity description: Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
-
A.
Regulation (EC) No 726/2004
Regulation (EC) No 726/2004 is an EU law that establishes the centralized procedure for the authorization and supervision of medicinal products and defines the role and powers of the European Medicines Agency.
-
B.
Orphan Drug Act of 1983
The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
-
C.
Committee for Orphan Medicinal Products
The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
-
D.
Regulation (EC) No 45/2001
Regulation (EC) No 45/2001 is an EU law that sets out data protection rules for the processing of personal data by EU institutions and bodies.
-
E.
Council Regulation (EC) No 1/2003
Council Regulation (EC) No 1/2003 is a key European Union law that modernized and decentralized the enforcement of EU competition rules, particularly Articles 101 and 102 of the Treaty on the Functioning of the European Union.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00845ca68819081a2ce3ecca577f7 |
completed | March 22, 2026, 3:18 p.m. |
| NER | Named-entity recognition | batch_69c02a905da88190bc710c6743af2d83 |
completed | March 22, 2026, 5:44 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c09824c7f0819095565e0f29b3a508 |
completed | March 23, 2026, 1:32 a.m. |
| NEDg | Description generation | batch_69c098a0325c81909a1326b94e40ed50 |
completed | March 23, 2026, 1:34 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69c09943deec819085992c4e44050a34 |
completed | March 23, 2026, 1:37 a.m. |
Created at: March 22, 2026, 3:51 p.m.